<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04545333</url>
  </required_header>
  <id_info>
    <org_study_id>ADAP-008</org_study_id>
    <nct_id>NCT04545333</nct_id>
  </id_info>
  <brief_title>The clonoSEQ® Watch Registry</brief_title>
  <official_title>Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adaptive Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adaptive Biotechnologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, observational study of adult patients with a diagnosis of&#xD;
      acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia&#xD;
      (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50&#xD;
      sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in&#xD;
      the management of lymphoid malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data show that detection of MRD may be important to guide treatment decisions in ALL, MM,&#xD;
      CLL, and NHL. However, there remains a lack of real-world evidence for making therapeutic&#xD;
      decisions based upon MRD status. This study is designed to understand when in a patient's&#xD;
      treatment continuum the assay is used and how clonoSEQ MRD data impact the treatment&#xD;
      decisions made by investigators.&#xD;
&#xD;
      All patients enrolled in the study will be followed for at least 2 yrs. Demographic data and&#xD;
      disease status will be captured at study enrollment. Patients must be &gt;/= 18 yrs of age and&#xD;
      able to sign informed consent. A given patient is eligible to enroll in the study if the&#xD;
      treating physician has made the decision to use the clonoSEQ assay as part of that patient's&#xD;
      routine cancer care. Reasons for placing a clonoSEQ order and subsequent decisions made as a&#xD;
      result of MRD data will be tracked. Patient treatment will also be tracked over the course of&#xD;
      the study in order to understand how clonoSEQ use is incorporated into current treatment&#xD;
      regimens.&#xD;
&#xD;
      Participating centers will include sites that actively use clonoSEQ to manage their patients&#xD;
      with lymphoid malignancies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2020</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Distribution of timepoints at which MRD is monitored using the clonoSEQ Assay in lymphoid malignancy patients in real world settings</measure>
    <time_frame>up to 3 yrs</time_frame>
    <description>Data will be collected to determine at what points lymphoid malignancy patients are in their treatment continuums when the clonoSEQ Assay is used to monitor MRD levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numbers of lymphoid malignancy patients with intensifications to their drug regimens based upon clonoSEQ MRD results</measure>
    <time_frame>up to 3 yrs</time_frame>
    <description>Data will be collected with regard to changes to treatment/drug regimens in order to determine how clonoSEQ Assay MRD results inform and impact routine clinical practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of lymphoid malignancy patients with de-intensifications to their drug regimens based upon clonoSEQ MRD results</measure>
    <time_frame>up to 3 yrs</time_frame>
    <description>Data will be collected with regard to changes to treatment/drug regimens in order to determine how clonoSEQ Assay MRD results inform and impact routine clinical practice</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Average numbers of clonoSEQ Assay orders placed for enrolled lymphoid malignancy patients in routine clinical practice relative to other response assessments</measure>
    <time_frame>up to 3 yrs</time_frame>
    <description>Data will be collected to determine how the clonoSEQ Assay is used as part of routine disease response assessments in lymphoid malignancy patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Differences in outcomes between clonoSEQ Assay MRD-negative and MRD-positive lymphoid malignancy patients</measure>
    <time_frame>up to 3 yrs</time_frame>
    <description>Data will be collected to assess the following, as applicable, depending upon distribution of patients that enroll in this study:&#xD;
Response to treatment, duration of response, time to next therapy, duration of maintenance therapy, and survival&#xD;
Numbers of patients who proceed to transplant in the ALL and MM cohorts</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">528</enrollment>
  <condition>Acute Lymphoblastic Leukemia, Adult B-Cell</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Non-hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>ALL</arm_group_label>
    <description>patients diagnosed with acute lymphoblastic leukemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLL</arm_group_label>
    <description>patients diagnosed with chronic lymphocytic leukemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MM</arm_group_label>
    <description>patients diagnosed with multiple myeloma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NHL</arm_group_label>
    <description>patients diagnosed with non-Hodgkin lymphoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>clonoSEQ Assay</intervention_name>
    <description>minimal residual disease (MRD) assay using blood, bone marrow, or other tissue containing tumor cells</description>
    <arm_group_label>ALL</arm_group_label>
    <arm_group_label>CLL</arm_group_label>
    <arm_group_label>MM</arm_group_label>
    <arm_group_label>NHL</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Remaining samples will be stored for potential use in future assay development research.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with a diagnosis of ALL, MM, CLL, or NHL whose SOC response assessments will&#xD;
        include monitoring of MRD status by clonoSEQ Assay&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be able to provide written informed consent&#xD;
&#xD;
          2. A decision has been made by the treating provider to use the clonoSEQ Assay as part of&#xD;
             routine clinical care&#xD;
&#xD;
          3. Age ≥ 18 years;&#xD;
&#xD;
          4. Documented hematologic malignancy (any of the below):&#xD;
&#xD;
               1. MM&#xD;
&#xD;
               2. ALL (B and T-cell subtypes)&#xD;
&#xD;
               3. B-cell NHL (all sub types)&#xD;
&#xD;
               4. CLL&#xD;
&#xD;
               5. Other lymphoid malignancies (upon review and approval by study chair)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients must not meet any of the following criteria in order to be enrolled into the&#xD;
        study:&#xD;
&#xD;
          1. Concurrent enrollment in a clinical trial where treatment decisions and patterns are&#xD;
             dictated per protocol&#xD;
&#xD;
          2. A decision has been made by the treating provider to not use the clonoSEQ Assay as&#xD;
             part of routine clinical care&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Pagel, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Swedish Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heidi Simmons, PhD</last_name>
    <phone>206-279-2591</phone>
    <email>hsimmons@adaptivebiotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Schliekelman, PhD</last_name>
    <phone>206-279-2508</phone>
    <email>mschliekelman@adaptivebiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Hospital</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet McDowell</last_name>
    </contact>
    <investigator>
      <last_name>Lori Muffly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado - Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Schatz</last_name>
    </contact>
    <investigator>
      <last_name>Tomer Mark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Lai</last_name>
    </contact>
    <investigator>
      <last_name>Catherine Lai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Georgi</last_name>
    </contact>
    <investigator>
      <last_name>Georges Azzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edward H. Kaplan MD &amp; Associates</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlon Kleinman</last_name>
    </contact>
    <investigator>
      <last_name>Marlon Kleinman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Clinic</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Castine</last_name>
    </contact>
    <investigator>
      <last_name>Michael Castine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Oncology Partners of Maryland</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Cheson</last_name>
    </contact>
    <investigator>
      <last_name>Bruce Cheson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Fiala</last_name>
    </contact>
    <investigator>
      <last_name>Ravi Vij, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Skarbnik</last_name>
    </contact>
    <investigator>
      <last_name>Alan Skarbnik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University, Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Lundberg Williams</last_name>
    </contact>
    <investigator>
      <last_name>Jessica Leonard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Walsh</last_name>
    </contact>
    <investigator>
      <last_name>Jakub Svoboda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours St Francis</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Adams</last_name>
    </contact>
    <investigator>
      <last_name>Howland Crosswell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington, Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Wilcox</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Cowan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krish Patel</last_name>
    </contact>
    <investigator>
      <last_name>Krish Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialists</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Kerry</last_name>
    </contact>
    <investigator>
      <last_name>Swathi Namburi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Swathi Namburi</last_name>
    </contact>
    <investigator>
      <last_name>Swathi Namburi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Minimal residual disease</keyword>
  <keyword>measurable residual disease</keyword>
  <keyword>MRD</keyword>
  <keyword>clonoSEQ</keyword>
  <keyword>ALL</keyword>
  <keyword>CLL</keyword>
  <keyword>MM</keyword>
  <keyword>NHL</keyword>
  <keyword>Watch Registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

